Xiang Gao1, Kelly C Simon, Michael A Schwarzschild, Alberto Ascherio. 1. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. xiang.gao@channing.harvard.edu
Abstract
OBJECTIVE: To prospectively examine whether use of statins is associated with altered risk of Parkinson disease (PD). DESIGN, SETTING, AND PARTICIPANTS: A prospective study including 38 192 men and 90 874 women participating in 2 ongoing US cohorts, the Health Professional Follow-up Study and the Nurses' Health Study, was conducted. Information on regular cholesterol-lowering drug use (≥2 times/wk) was collected in 1994 in both cohorts via questionnaire. Relative risks (RRs) and 95% CIs were computed using Cox proportional hazards models adjusting for age, smoking, caffeine intake, duration of hypercholesterolemia, and other covariates. MAIN OUTCOME MEASURE: Incident PD. RESULTS: During 12 years of follow-up (1994-2006), we documented 644 incident PD cases (338 women and 306 men). The risk of PD was lower among current statin users (adjusted pooled RR = 0.74; 95% CI, 0.54-1.00; P = .049) relative to nonusers. A significant association was observed in participants younger than 60 years at baseline (adjusted pooled RR = 0.31; 95% CI, 0.11-0.86; P = .02) but not among those who were older (adjusted pooled RR = 0.83; 95% CI, 0.60-1.14; P = .25) (P for interaction = .03). CONCLUSIONS: We found that regular use of statins was associated with a modest reduction in PD risk. The possibility that some statins may reduce PD risk deserves further consideration.
OBJECTIVE: To prospectively examine whether use of statins is associated with altered risk of Parkinson disease (PD). DESIGN, SETTING, AND PARTICIPANTS: A prospective study including 38 192 men and 90 874 women participating in 2 ongoing US cohorts, the Health Professional Follow-up Study and the Nurses' Health Study, was conducted. Information on regular cholesterol-lowering drug use (≥2 times/wk) was collected in 1994 in both cohorts via questionnaire. Relative risks (RRs) and 95% CIs were computed using Cox proportional hazards models adjusting for age, smoking, caffeine intake, duration of hypercholesterolemia, and other covariates. MAIN OUTCOME MEASURE: Incident PD. RESULTS: During 12 years of follow-up (1994-2006), we documented 644 incident PD cases (338 women and 306 men). The risk of PD was lower among current statin users (adjusted pooled RR = 0.74; 95% CI, 0.54-1.00; P = .049) relative to nonusers. A significant association was observed in participants younger than 60 years at baseline (adjusted pooled RR = 0.31; 95% CI, 0.11-0.86; P = .02) but not among those who were older (adjusted pooled RR = 0.83; 95% CI, 0.60-1.14; P = .25) (P for interaction = .03). CONCLUSIONS: We found that regular use of statins was associated with a modest reduction in PD risk. The possibility that some statins may reduce PD risk deserves further consideration.
Authors: Alberto Ascherio; Peter A LeWitt; Kui Xu; Shirley Eberly; Arthur Watts; Wayne R Matson; Connie Marras; Karl Kieburtz; Alice Rudolph; Mikhail B Bogdanov; Steven R Schwid; Marsha Tennis; Caroline M Tanner; M Flint Beal; Anthony E Lang; David Oakes; Stanley Fahn; Ira Shoulson; Michael A Schwarzschild Journal: Arch Neurol Date: 2009-12
Authors: J A Human; J B Ubbink; J J Jerling; R Delport; W J Vermaak; H H Vorster; J Lagendijk; H C Potgieter Journal: Clin Chim Acta Date: 1997-07-04 Impact factor: 3.786
Authors: Xuemei Huang; Alvaro Alonso; Xuguang Guo; David M Umbach; Maya L Lichtenstein; Christie M Ballantyne; Richard B Mailman; Thomas H Mosley; Honglei Chen Journal: Mov Disord Date: 2015-01-14 Impact factor: 10.338
Authors: Thanh G N Ton; Mary Lou Biggs; Diane Comer; Lesley Curtis; Shu-Ching Hu; Evan L Thacker; Susan Searles Nielsen; Joseph A Delaney; Douglas Landsittel; William T Longstreth; Harvey Checkoway; Samay Jain Journal: Pharmacoepidemiol Drug Saf Date: 2013-12-13 Impact factor: 2.890
Authors: Naiani F Marques; Adalberto A Castro; Gianni Mancini; Fernanda L Rocha; Adair R S Santos; Rui D Prediger; Andreza Fabro De Bem; Carla I Tasca Journal: Neurotox Res Date: 2017-11-21 Impact factor: 3.911
Authors: Benjamin L Deck; Jacqueline Rick; Sharon X Xie; Alice Chen-Plotkin; John E Duda; James F Morley; Lana M Chahine; Nabila Dahodwala; John Q Trojanowski; Daniel Weintraub Journal: J Parkinsons Dis Date: 2017 Impact factor: 5.568
Authors: Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin Journal: Ann Neurol Date: 2013-08-06 Impact factor: 10.422